New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis

Franco Frati,1 Lorenzo Cecchi,2,3 Enrico Scala,4 Erminia Ridolo,5 Ilaria Dell'Albani,1 Eleni Makrì,6 Giovanni Pajno,7 Cristoforo Incorvaia6 1Medical and Scientific Department, Stallergenes, Milan, Italy; 2Interdepartmental Centre of Bioclimatology, University of Florence, Florenc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Frati F, Cecchi L, Scala E, Ridolo E, Dell'Albani I, Makrì E, Pajno G, Incorvaia C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ac21c935e5bc48b2a71bbabcfaa02d42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac21c935e5bc48b2a71bbabcfaa02d42
record_format	dspace
spelling	oai:doaj.org-article:ac21c935e5bc48b2a71bbabcfaa02d422021-12-02T01:27:50ZNew product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis1177-5491https://doaj.org/article/ac21c935e5bc48b2a71bbabcfaa02d422014-09-01T00:00:00Zhttp://www.dovepress.com/new-product-development-with-the-innovative-biomolecular-sublingual-im-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491 Franco Frati,1 Lorenzo Cecchi,2,3 Enrico Scala,4 Erminia Ridolo,5 Ilaria Dell'Albani,1 Eleni Makrì,6 Giovanni Pajno,7 Cristoforo Incorvaia6 1Medical and Scientific Department, Stallergenes, Milan, Italy; 2Interdepartmental Centre of Bioclimatology, University of Florence, Florence, Italy; 3Allergy and Clinical Immunology Section, Azienda Sanitaria di Prato, Prato, Italy; 4Experimental Allergy Unit, IDI-IRCCS, Rome, Italy; 5Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy; 6Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, Italy; 7Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy Abstract: The molecular allergy technique, currently defined as component-resolved diagnosis, significantly improved the diagnosis of allergy, allowing for differentiation between molecules actually responsible for clinical symptoms (genuine sensitizers) and those simply cross-reacting or shared by several sources (panallergens), thus influencing the appropriate management of a patient's allergy. This also concerns allergen immunotherapy (AIT), which may be prescribed more precisely based on the component-resolved diagnosis results. However, the advance in diagnosis needs to be mirrored in AIT. According to consensus documents and to expectations of specialists, therapy should be based on standardized extracts containing measured amounts of the clinically relevant molecules, ie, the major allergens. The new generation of extracts for sublingual immunotherapy fulfills these requirements and are thus defined as biomolecular (BM). BM refers to natural extracts with a defined content of major allergens in micrograms. All Staloral BM products are indicated for the treatment of allergic rhinitis with or without asthma. The effectiveness of AIT is related to its ability to modify the immunological response of allergic subjects. The 5-grass and house dust mite extracts were evaluated addressing the T helper 1, T helper 2, and T helper 3 cells by polymerase chain reaction array on mRNA extracted from Waldeyer's ring tissue (adenoids). Sublingual immunotherapy with a defined content of major allergens in micrograms induced a strong downregulation of genes involved in T helper 2 and T helper 1 activation and function, allowing the definition of the immunologic effect as "bio-homeostatic". This clinical and immunological model must be implemented with respect to other allergens, thus expanding the application of a treatment with a unique disease-modifying capacity. Keywords: allergen immunotherapy, allergy, component resolved diagnosis, major allergens, allergen moleculesFrati FCecchi LScala ERidolo EDell'Albani IMakrì EPajno GIncorvaia CDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 221-226 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Frati F Cecchi L Scala E Ridolo E Dell'Albani I Makrì E Pajno G Incorvaia C New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
description	Franco Frati,1 Lorenzo Cecchi,2,3 Enrico Scala,4 Erminia Ridolo,5 Ilaria Dell'Albani,1 Eleni Makrì,6 Giovanni Pajno,7 Cristoforo Incorvaia6 1Medical and Scientific Department, Stallergenes, Milan, Italy; 2Interdepartmental Centre of Bioclimatology, University of Florence, Florence, Italy; 3Allergy and Clinical Immunology Section, Azienda Sanitaria di Prato, Prato, Italy; 4Experimental Allergy Unit, IDI-IRCCS, Rome, Italy; 5Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy; 6Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, Italy; 7Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy Abstract: The molecular allergy technique, currently defined as component-resolved diagnosis, significantly improved the diagnosis of allergy, allowing for differentiation between molecules actually responsible for clinical symptoms (genuine sensitizers) and those simply cross-reacting or shared by several sources (panallergens), thus influencing the appropriate management of a patient's allergy. This also concerns allergen immunotherapy (AIT), which may be prescribed more precisely based on the component-resolved diagnosis results. However, the advance in diagnosis needs to be mirrored in AIT. According to consensus documents and to expectations of specialists, therapy should be based on standardized extracts containing measured amounts of the clinically relevant molecules, ie, the major allergens. The new generation of extracts for sublingual immunotherapy fulfills these requirements and are thus defined as biomolecular (BM). BM refers to natural extracts with a defined content of major allergens in micrograms. All Staloral BM products are indicated for the treatment of allergic rhinitis with or without asthma. The effectiveness of AIT is related to its ability to modify the immunological response of allergic subjects. The 5-grass and house dust mite extracts were evaluated addressing the T helper 1, T helper 2, and T helper 3 cells by polymerase chain reaction array on mRNA extracted from Waldeyer's ring tissue (adenoids). Sublingual immunotherapy with a defined content of major allergens in micrograms induced a strong downregulation of genes involved in T helper 2 and T helper 1 activation and function, allowing the definition of the immunologic effect as "bio-homeostatic". This clinical and immunological model must be implemented with respect to other allergens, thus expanding the application of a treatment with a unique disease-modifying capacity. Keywords: allergen immunotherapy, allergy, component resolved diagnosis, major allergens, allergen molecules
format	article
author	Frati F Cecchi L Scala E Ridolo E Dell'Albani I Makrì E Pajno G Incorvaia C
author_facet	Frati F Cecchi L Scala E Ridolo E Dell'Albani I Makrì E Pajno G Incorvaia C
author_sort	Frati F
title	New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
title_short	New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
title_full	New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
title_fullStr	New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
title_full_unstemmed	New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
title_sort	new product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/ac21c935e5bc48b2a71bbabcfaa02d42
work_keys_str_mv	AT fratif newproductdevelopmentwiththeinnovativebiomolecularsublingualimmunotherapyformulationsforthemanagementofallergicrhinitis AT cecchil newproductdevelopmentwiththeinnovativebiomolecularsublingualimmunotherapyformulationsforthemanagementofallergicrhinitis AT scalae newproductdevelopmentwiththeinnovativebiomolecularsublingualimmunotherapyformulationsforthemanagementofallergicrhinitis AT ridoloe newproductdevelopmentwiththeinnovativebiomolecularsublingualimmunotherapyformulationsforthemanagementofallergicrhinitis AT dellalbanii newproductdevelopmentwiththeinnovativebiomolecularsublingualimmunotherapyformulationsforthemanagementofallergicrhinitis AT makrie newproductdevelopmentwiththeinnovativebiomolecularsublingualimmunotherapyformulationsforthemanagementofallergicrhinitis AT pajnog newproductdevelopmentwiththeinnovativebiomolecularsublingualimmunotherapyformulationsforthemanagementofallergicrhinitis AT incorvaiac newproductdevelopmentwiththeinnovativebiomolecularsublingualimmunotherapyformulationsforthemanagementofallergicrhinitis
_version_	1718403094638755840

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis

Ejemplares similares